发文地区与机构
近年国家 / 地区发文量统计
| 国家 / 地区 | 发文量 |
|---|---|
| USA | 353 |
| CHINA MAINLAND | 289 |
| Italy | 210 |
| England | 139 |
| GERMANY (FED REP GER) | 89 |
| France | 77 |
| Spain | 65 |
| Japan | 54 |
| Australia | 42 |
| Canada | 40 |
近年机构发文量统计
| 机构 | 发文量 |
|---|---|
| UNIVERSITY OF TEXAS SYSTEM | 49 |
| UNICANCER | 43 |
| PFIZER | 40 |
| HARVARD UNIVERSITY | 35 |
| SHANDONG FIRST MEDICAL UNIVERSITY & SHA... | 28 |
| SUN YAT SEN UNIVERSITY | 27 |
| UNIVERSITY OF LONDON | 27 |
| FUDAN UNIVERSITY | 26 |
| UNIVERSITY OF CALIFORNIA SYSTEM | 26 |
| FONDAZIONE IRCCS ISTITUTO NAZIONALE TUM... | 25 |
文章引用情况
1
By downregulating PBX miR-526b suppresses the epithelial-mesenchymal transition process in cervical cancer cells2
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer3
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale4
Understanding the nuances of microwave ablation for more accurate post-treatment assessment5
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design6
Denosumab for the treatment of bone disease in solid tumors and multiple myeloma7
Curcumin exerts cytotoxicity dependent on reactive oxygen species accumulation in non-small-cell lung cancer cells8
Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib9
Necitumumab for the treatment of advanced non-small-cell lung cancer10
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer